title: How HIV treatment advances affect the cost-effectiveness of prevention.
abstract: OBJECTIVE
  The cost-effectiveness of an HIV prevention program depends, in part, on its potential to avert HIV-related medical care costs. Recent advances in antiretroviral therapy have made HIV/AIDS treatment both more effective and more costly, which might make HIV prevention either more or less cost-effective. The objective of the present study was to explicate the relationship between the effectiveness and costs of HIV treatment and the cost-effectiveness of HIV prevention programs.
  
  
  METHODS
  A basic analytic framework was used to compare the cost-effectiveness of HIV prevention interventions with respect to different HIV/AIDS medical care scenarios. Algebra was used to calculate a cost-effectiveness threshold that distinguishes prevention programs that become more cost-effective when therapeutic advances simultaneously increase or decrease the cost and effectiveness of treatment from those that become less cost-effective. Recent estimates of the costs and consequences of combination antiretroviral therapy were used to illustrate the calculation method.
  
  
  RESULTS
  The advent of combination antiretroviral therapies for HIV has increased the cost-effectiveness of some, but not all, HIV prevention interventions.
  
  
  CONCLUSIONS
  Whether a particular prevention program becomes more or less cost-effective as a consequence of advancements in the medical treatment of HIV/AIDS depends upon the specific characteristics of both the program and the therapy.
authors.affiliation: Department of Psychiatry and Behavioral Medicine, Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee 53202, USA. pinkrton@mcw.edu
authors.forename: S D
authors.initials: SD
authors.lastname: Pinkerton
authors.forename: D R
authors.initials: DR
authors.lastname: Holtgrave
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D008017:Life Expectancy; D008297:Male; D019057:Quality-Adjusted Life Years
chemical_list: D019380:Anti-HIV Agents